Preterm Birth Prevention and Management Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 – 2034

The Global Preterm Birth Prevention And Management Market was valued at USD 1.8 billion in 2024 and is projected to expand at a CAGR of 7.7% from 2025 to 2034. This remarkable growth is driven by several factors, including rising rates of preterm births, advancements in medical technology, an increasing prevalence of maternal risk factors, and a heightened focus on improving neonatal care.

The market encompasses a range of therapies designed to prevent and manage preterm births, including tocolytic therapy, progesterone therapy, antibiotics therapy, corticosteroid therapy, heparin prophylaxis therapy, and other treatment options. Among these, progesterone therapy is expected to lead the market, growing at a CAGR of 8% and generating USD 1.5 billion by 2034. Progesterone has been extensively studied and proven to significantly reduce the risk of preterm births, particularly in women with a history of spontaneous preterm deliveries or those at high risk. Its proven effectiveness in preventing early labor, especially for women with a short cervix or multiple pregnancies, contributes to its widespread adoption as a primary preventative measure.

The market is also segmented by the route of administration, which includes parenteral, oral, and topical options. The parenteral administration segment is anticipated to experience robust growth, with a projected CAGR of 7.6%, reaching USD 2.7 billion by 2034. Parenteral administration, especially via intravenous (IV) or intramuscular (IM) routes, offers more rapid and efficient delivery of critical drugs like progesterone or tocolytics. This method is essential for high-risk pregnancies, as it bypasses the digestive system, ensuring more consistent and controlled dosing, which makes it a preferred option in clinical settings.

In the U.S., the preterm birth prevention and management market was valued at USD 671.6 million in 2024 and is expected to grow at a CAGR of 7.2% between 2025 and 2034. The U.S. faces a relatively high rate of preterm births compared to other developed nations, creating a pressing need for effective strategies to prevent and manage these early deliveries. This challenge drives the demand for advanced therapies, remedies, and innovative solutions. Furthermore, the U.S. remains a global leader in maternal-fetal medicine research, contributing to the development of cutting-edge technologies and practices designed to prevent and manage preterm births.